Pharmidex provides comprehensive analytical services to support the characterisation, quantification and translational assessment of therapeutic candidates from discovery through preclinical development. Our offering spans small molecules, peptides, biologics, RNA therapeutics, antibody-drug conjugates and viral vectors, with capabilities tailored to both discovery research and regulated (GLP-aligned) studies. Core analytical services include bioanalysis, quantitative LC-MS/MS, ligand-binding assays, qPCR, ELISA, immunogenicity assays, protein/peptide characterisation, drug metabolite identification, TK bioanalysis, and clinical sample analysis. We develop and validate bespoke analytical methods, including high-sensitivity assays suitable for challenging matrices such as CSF, tumour tissue, brain and BALF. Our LC-MS/MS platforms enable high-throughput quantitative measurement of drug and metabolite levels with robust lower limits of quantification, supporting PK, PD, TK and biodistribution studies. Our ligand-binding and qPCR assays enable measurement of biologics and genetic modalities, including viral vector copy number and siRNA quantification. We also support dose formulation analysis, stability studies, solubility, and impurity profiling. Pharmidex differentiates through integrated scientific input, regulatory awareness and fast assay development cycles. Analytical scientists work directly with in vivo pharmacology and DMPK teams to ensure coherent study design, data interpretation and decision-making. We operate GLP-accredited facilities and support transfer of validated methods to clinical CROs upon request. Our mission is to provide early-stage companies and biotech innovators with reliable, decision-enabling analytical data that accelerates optimisation, de-risks development and supports progression toward IND/CTA filings. All generated data and IP remain with the client, and services are offered flexibly on a fee-for-service basis.